Immunosuppressive drugs
Immunosuppressive drugs
Pharmaceutical form and use |
ATC group |
Drug name |
COVID vaccination |
Tablets, daily use |
L04AA |
Mycophenolic acid, Rapamune, Certican, Arava, Gilenya, Xeljanz, Aubagio, Otezla, Olumiant, Mayzent |
Yes. All vaccines are eligible, no change in treatment due to vaccination unless the treating physician recommends a change. |
L04AD |
Sandimmun, tacrolimus (e.g. Prograf) |
||
L04AX |
Imurel, thalidomide, methotrexate, Esbriet, Tecfidera |
||
H02AB |
Steroids, e.g. hydrocortisone |
Yes. All vaccines are eligible, no change in treatment due to vaccination unless the treating physician recommends a change. Note that individuals with cortisol deficiency may need to increase their doses due to vaccination. |
|
Tablets, irregular use |
L04AA |
Mavenclad |
In consultation with the treating physician, vaccination may need to be scheduled individually, such as according to blood levels. See also here. |
L04AX |
Lenalidomid, Imnovid |
||
Intravenous infusion administered approx. every 4 weeks |
L04AA |
Tysabri, Orencia, Entyvio |
In consultation with treating physician, see also here. |
L04AC |
RoActemra, Cosentyx |
||
Intravenous infusion or injection administered at intervals of less than 3 months |
L04AB |
Infliximab (e.g. Flixabi) |
Yes. Vaccines should be used with as little time as possible between doses, and the timing of the first vaccination should be approx. when it is time for a dose and vaccination should be completed before the dose is administered if possible. |
L04AC |
Stelara, Ilaris, Tremfya |
||
Intravenous infusion or injection administered approx. every 3–6 months |
L04AA |
Ocrevus |
Yes. Vaccines should be used with as little time as possible between doses, and the timing of the first vaccination should be approx. 4–5 weeks before it is time for a dose and vaccination should be completed before the dose is administered. |
Subcutaneous injection daily, can be administered at home |
L04AC |
Anakinra (Kineret) |
Yes. All vaccines are eligible, no change in treatment due to vaccination unless the treating physician recommends a change. |
Subcutaneous injection, usually approx. every 2 weeks, can be administered at home |
L04AA |
Benlysta |
Yes. All vaccines are eligible. No need to skip a dose, schedule vaccination in between doses. |
L04AB |
Etanercept (Benepali, Enbrel), adalimumab (Humira, Imraldi, etc.), golimumab (Simponi) |
Yes. All vaccines are eligible. Vaccination should be scheduled when it is time for a dose and that dose should be skipped, but the next dose should be taken according to schedule. If is not considered desirable to skip a dose, vaccination may be given in between doses. |
|
L04AC |
Kyntheum, Taltz |
||
Infusion, irregular use |
L04AC |
Basiliximab |
All vaccines are eligible, but circumstances may call for one rather than another. It is desirable to give the first dose of vaccine when 6 months have elapsed from administration but at least 2 weeks after the last dose and preferably 2–4 weeks before re-administration of drugs in these groups and in consultation with the treating physician. |
L01XC02 |
Rituximab (e.g. MabThera) |
This table is prepared by the Chief Epidemiologist in consultation with specialists who use these drugs, i.a. rheumatologists, hematologists, neurologists and nephrologists.
Fyrst birt 04.01.2022
Síðast uppfært 04.01.2022